Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galcanezumab - Eli Lilly and Company

Drug Profile

Galcanezumab - Eli Lilly and Company

Alternative Names: Emgality; Galcanezumab-gnlm; LY-2951742

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Migraine
  • Phase I Unspecified
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 21 Sep 2021 Biomarkers information updated
  • 14 Jul 2021 Eli Lilly and Company completes the phase III REGAIN trial in Chronic migraine (Prevention) in USA, Argentina, Canada, Brazil, Czech Republic, Germany, Israel, Italy, Mexico, the Netherlands, Puerto Rico, Spain, Taiwan, UK (SC) (NCT02614261) (EudraCT2015-001883-21)
  • 23 Jun 2021 Launched for Migraine (In adolescents, Prevention, In children, Treatment-resistant) in USA (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top